Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $839,466.36 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 10,602 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $79.18, for a total value of $839,466.36. Following the completion of the sale, the executive vice president owned 21,759 shares of the company’s stock, valued at $1,722,877.62. This represents a 32.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Price Performance

IONS opened at $81.18 on Monday. The company has a market capitalization of $13.42 billion, a price-to-earnings ratio of -39.22 and a beta of 0.37. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. Ionis Pharmaceuticals, Inc. has a 12-month low of $39.37 and a 12-month high of $86.74. The business’s fifty day simple moving average is $75.03 and its 200-day simple moving average is $77.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm had revenue of $246.09 million during the quarter, compared to the consensus estimate of $195.56 million. During the same period in the previous year, the company posted ($0.93) earnings per share. The firm’s quarterly revenue was up 86.4% on a year-over-year basis. On average, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in Ionis Pharmaceuticals by 318.1% in the first quarter. Empowered Funds LLC now owns 103,141 shares of the company’s stock worth $7,745,000 after purchasing an additional 78,470 shares during the last quarter. Carmignac Gestion purchased a new stake in shares of Ionis Pharmaceuticals during the 1st quarter valued at $3,980,000. Perceptive Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 1st quarter valued at $37,845,000. Groupama Asset Managment boosted its position in shares of Ionis Pharmaceuticals by 7.5% in the 1st quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock worth $61,915,000 after purchasing an additional 57,651 shares in the last quarter. Finally, Stempoint Capital LP acquired a new stake in shares of Ionis Pharmaceuticals in the 1st quarter worth $1,981,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
• Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
• Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IONS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 21st. The Goldman Sachs Group lifted their price objective on shares of Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday. Citigroup initiated coverage on shares of Ionis Pharmaceuticals in a research note on Monday, May 18th. They issued a “buy” rating and a $115.00 price objective for the company. TD Cowen restated a “buy” rating and set a $108.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, June 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $111.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $102.90.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.